Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Improving long-term quality of life in prostate cancer treatment

Duncan Gilbert • 16 Sep 2024
ESMO 2024
Genitourinary Cancer Prostate Cancer

Duncan Gilbert, MA, MRCP, FRCR, PhD, University College London, London, UK, provides an overview of recent prostate cancer research, focusing on patient choice and improving long-term quality of life for men undergoing androgen suppression. Novel strategies to address treatment-related toxicities in this population have been evaluated in trials. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Duncan Gilbert

The future of transdermal estradiol in managing prostate cancer
1:11
The future of transdermal estradiol in managing prostate cancer
Duncan Gilbert • 16 Sep 2024
Estrogen patches as a safer androgen suppression alternative in prostate cancer
2:00
Estrogen patches as a safer androgen suppression alternative in prostate cancer
Duncan Gilbert • 16 Sep 2024
Transdermal estradiol for androgen suppression in locally advanced prostate cancer
1:10
Transdermal estradiol for androgen suppression in locally advanced prostate cancer
Duncan Gilbert • 16 Sep 2024
PATCH: transdermal estradiol versus LH-RH analogues in prostate cancer
1:29
PATCH: transdermal estradiol versus LH-RH analogues in prostate cancer
Duncan Gilbert • 16 Sep 2024

Related Videos

Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
3:36
EV plus pembrolizumab improves perioperative outcomes in muscle-invasive bladder cancer
Tian Zhang • 1 Jun 2026
Drug repurposing and trial challenges in rare renal medullary carcinoma
3:11
Drug repurposing and trial challenges in rare renal medullary carcinoma
Pavlos Msaouel • 30 May 2026
The content of VJOncology is intended for healthcare professionals